CYCC Gets $7Mln Strategic Investment, SUPN Abuzz, SNGX Plunges On Oral Mucositis Trial Data
CYCC Gets $7Mln Strategic Investment, SUPN Abuzz, SNGX Plunges On Oral Mucositis Trial Data WASHINGTON (dpa-AFX) - Todays Daily Dose brings you news about BioCrysts update on its investigational broad-spectrum antiviral Galidesivir in the treatment of COVID-19, a $7 million strategic investment by Acorn Bioventures in Cyclacel Pharma, Supernus phase III study results of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder, and Spectrums progress with Poziotinib for no...
District Of Columbia United States Christopherj Schaber Cyclacel Pharma Cyclacel Pharmaceuticals Inc Beam Therapeutics Inc
Source: finanznachrichten.de